Shirley Brown

Imatinib Mesylate in Patients With Adenoid Cystic Cancers of the Salivary Glands Expressing c-kit: A Princess Margaret Hospital Phase II Consortium Study

Sebastién J. Hotte, Eric Winquist, Elizabeth B. Lamont et al. · Journal of Clinical Oncology · 2005 · 280 citations

Medicine, Oncology, Cancer Pharmacology +13

Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non–Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands

Mark Agulnik, Ezra E.W. Cohen, Roger B. Cohen et al. · Journal of Clinical Oncology · 2007 · 263 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumours

M. Cianfrocca, Kathryn A. Kimmel, James M. Gallo et al. · British Journal of Cancer · 2006 · 177 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15

Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid Tumors

Lillian L. Siu, Ignacio Durán, Wells A. Messersmith et al. · Journal of Clinical Oncology · 2008 · 118 citations

Medicine, Oncology, Pharmacology +16

UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: A study of the Princess Margaret Hospital Phase II consortium

Stephen Welch, Hal W. Hirte, Mark S. Carey et al. · Gynecologic Oncology · 2007 · 76 citations

Medicine, Gynecology, Oncology +10